vTv Therapeutics (NASDAQ:VTVT) Shares Cross Below Fifty Day Moving Average – Here’s Why

vTv Therapeutics Inc. (NASDAQ:VTVT)’s share price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $33.17 and traded as low as $31.55. vTv Therapeutics shares last traded at $31.95, with a volume of 52,700 shares.

Analyst Ratings Changes

VTVT has been the topic of several analyst reports. Zacks Research lowered shares of vTv Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. HC Wainwright cut their price target on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Rodman & Renshaw started coverage on vTv Therapeutics in a report on Tuesday, June 30th. They set a “buy” rating and a $67.00 price objective for the company. Wall Street Zen cut shares of vTv Therapeutics from a “buy” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings lowered shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Six analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, vTv Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Trading Up 0.2%

The firm has a 50-day simple moving average of $33.12 and a two-hundred day simple moving average of $34.57. The stock has a market cap of $131.87 million, a P/E ratio of -31.58 and a beta of 0.29.

vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08). Sell-side analysts predict that vTv Therapeutics Inc. will post -2.35 earnings per share for the current year.

Institutional Investors Weigh In On vTv Therapeutics

A number of large investors have recently bought and sold shares of VTVT. 683 Capital Management LLC bought a new position in vTv Therapeutics in the 4th quarter valued at about $731,000. Goldman Sachs Group Inc. bought a new stake in vTv Therapeutics during the fourth quarter worth $221,000. Finally, Geode Capital Management LLC boosted its holdings in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares in the last quarter. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.